Table 3.
Table 3A: Main effects models (no interaction terms). Outcome: log titers to DENV-1
| Parameter | Regression parameter (beta) | P value | Overall P value |
|---|---|---|---|
| Virus passage | |||
| Low passage wild type | −0.2714 | 0.0760 | |
| Prototype | 0 (ref) | – | < 0.001 |
| Prototype in tissue culture | −0.6222 | < 0.001 | |
| Cell line | |||
| BHK21 | −0.5212 | < 0.001 | < 0.001 |
| Vero | 0 (ref) | – | |
| LLC-MK2 | 0.04403 | 0.7729 | |
| Infecting serotype | |||
| DENV-1 | 0 (ref) | – | |
| DENV-2 | −0.2674 | 0.6473 | 0.6013 |
| DENV-3 | −0.7297 | 0.1762 | |
| DENV-4 | −0.2837 | 0.6723 | |
| Complement | |||
| Absent | 0 (ref) | – | < 0.001 |
| Present | 0.5137 | < 0.001 | |
| Primary or secondary | |||
| Primary | 0 (ref) | – | 0.4694 |
| Secondary | 0.3246 | 0.4694 | |
| Intercept | 5.0871 | < 0.001 | |
| Table 3B: Main effects models (no interaction terms). Outcome: log titers to DENV-2 | |||
| Parameter | Regression parameter (beta) | P value | Overall P value |
| Virus passage | |||
| Low passage wild type | −0.2706 | 0.0093 | 0.0232 |
| Prototype | 0 (ref) | – | |
| Prototype in tissue culture | −0.2140 | 0.0393 | |
| Cell line | |||
| BHK21 | −0.7510 | < 0.001 | < 0.001 |
| Vero | 0 (ref) | – | |
| LLC-MK2 | −0.02935 | 0.7767 | |
| Infecting serotype | |||
| DENV-1 | −0.9151 | 0.0862 | |
| DENV-2 | 0 (ref) | – | 0.1879 |
| DENV-3 | −0.8966 | 0.1008 | |
| DENV-4 | −0.00623 | 0.9921 | |
| Complement | |||
| Absent | 0 (ref) | – | < 0.001 |
| Present | 0.5263 | < 0.001 | |
| Primary or secondary | |||
| Primary | 0 (ref) | – | 0.0293 |
| Secondary | 0.9504 | 0.0293 | |
| Intercept | 4.3889 | < 0.001 | |
| Table 3C: Main effects models (no interaction terms). Outcome: log titers to DENV-3 | |||
| Parameter | Regression parameter (beta) | P value | Overall P value |
| Virus passage | |||
| Low passage wild type | 1.3049 | < 0.001 | < 0.001 |
| Prototype | 0 (ref) | – | |
| Prototype in tissue culture | 0.07537 | 0.4302 | |
| Cell line | |||
| BHK21 | −0.1354 | 0.1569 | < 0.001 |
| Vero | 0 (ref) | – | |
| LLC-MK2 | 0.4500 | < 0.001 | |
| Infecting serotype | |||
| DENV-1 | −0.3771 | 0.03870 | |
| DENV-2 | 0.5760 | 0.2348 | 0.2548 |
| DENV-3 | 0 (ref) | – | |
| DENV-4 | 0.1091 | 0.8415 | |
| Complement | |||
| Absent | 0 (ref) | – | < 0.001 |
| Present | 0.4544 | < 0.001 | |
| Primary or secondary | |||
| Primary | 0 (ref) | – | 0.1693 |
| Secondary | 0.5311 | 0.1693 | |
| Intercept | 2.8795 | 0.0012 | |
| Table 3D: Main effects models (no interaction terms. Outcome: log titers to DENV-4 | |||
| Parameter | Regression parameter (beta) | P value | Overall P value |
| Virus passage | |||
| Low passage wild type | −0.1620 | 0.0496 | 0.0017 |
| Prototype | 0 (ref) | – | |
| Prototype in tissue culture | 0.1961 | < 0.001 | |
| Cell line | |||
| BHK21 | −0.3623 | < 0.001 | 0.0014 |
| Vero | 0 (ref) | – | |
| LLC-MK2 | −0.2125 | 0.0334 | |
| Infecting serotype | |||
| DENV-1 | −1.2953 | 0.0015 | |
| DENV-2 | −0.4726 | 0.2582 | 0.0013 |
| DENV-3 | −1.3743 | < 0.001 | |
| DENV-4 | 0 (ref) | – | |
| Complement | |||
| Absent | 0 (ref) | – | < 0.001 |
| Present | 0.4219 | < 0.001 | |
| Primary or Secondary | |||
| Primary | 0 (ref) | – | 0.0950 |
| Secondary | 0.4820 | 0.0950 | |
| Intercept | 4.4952 | < 0.001 | |
Table 3A–D display the output from the four multivariate, linear, mixed-effects models for the log antibody titers to DENV-1–4. No interaction terms were included in the main effects models. These results are based on the titers observed for the “follow-up specimens” for each dengue patient (collected 6–12 months after presentation); the results from acute specimens are excluded. Multiple tests were run on each sample and therefore a random intercept for the effect of each sample was included in the model. The values of each intercept were of secondary interest and are excluded from the tables. P values shown in bold are those that were significant at an α-level of 0.05.